In This Section      
 

Search Results

Title:
GY016 A Phase II Study of MK-3475 (Pembrolizumab) and Epacadostat in Recurrent Clear Cell Carcinoma of the Ovary
Protocol Number:
NCTNGY016
Phase:
Phase II
Physician:
Stephanie Gaillard
Sites:
Johns Hopkins Kimmel Cancer Center in Baltimore
Purpose:
This study is being done to test if the combination of two drugs (MK-3475 (pembrolizumab) and epacadostat) can stop your cancer from growing.
Eligibility:
Women with clear cell ovarian cancer, which has recurred or has not responded to standard therapy.
Treatment:
If you decide to take part in this study, you will get the study drugs MK-3475 (pembrolizumab) and epacadostat until your disease gets worse or the side effects become too severe. After you finish your treatment, your doctor and study team will watch you for side effects. They will check you every 3 months for 2 years after treatment. After that, they will check you every 6 months for 3 years. This means you will keep seeing your doctor for 5 years after treatment, unless you decide to stop this study early. The chance of developing side effects from the study drugs after 5 years is extremely low, but can be treated by your doctor if this were to occur.
Population:
Adult
Last Update
03/05/2019 05:03 AM